These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 17266197)

  • 1. Identification of critical residues in novel drug metabolizing mutants of cytochrome P450 BM3 using random mutagenesis.
    van Vugt-Lussenburg BM; Stjernschantz E; Lastdrager J; Oostenbrink C; Vermeulen NP; Commandeur JN
    J Med Chem; 2007 Feb; 50(3):455-61. PubMed ID: 17266197
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of alkoxyresorufins as fluorescent substrates for cytochrome P450 BM3 and site-directed mutants.
    Lussenburg BM; Babel LC; Vermeulen NP; Commandeur JN
    Anal Biochem; 2005 Jun; 341(1):148-55. PubMed ID: 15866539
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural rationalization of novel drug metabolizing mutants of cytochrome P450 BM3.
    Stjernschantz E; van Vugt-Lussenburg BM; Bonifacio A; de Beer SB; van der Zwan G; Gooijer C; Commandeur JN; Vermeulen NP; Oostenbrink C
    Proteins; 2008 Apr; 71(1):336-52. PubMed ID: 17957765
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Laboratory evolution of P450 BM3 for mediated electron transfer yielding an activity-improved and reductase-independent variant.
    Nazor J; Dannenmann S; Adjei RO; Fordjour YB; Ghampson IT; Blanusa M; Roccatano D; Schwaneberg U
    Protein Eng Des Sel; 2008 Jan; 21(1):29-35. PubMed ID: 18093991
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oxygen activation and electron transfer in flavocytochrome P450 BM3.
    Ost TW; Clark J; Mowat CG; Miles CS; Walkinshaw MD; Reid GA; Chapman SK; Daff S
    J Am Chem Soc; 2003 Dec; 125(49):15010-20. PubMed ID: 14653735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Application of drug metabolising mutants of cytochrome P450 BM3 (CYP102A1) as biocatalysts for the generation of reactive metabolites.
    Damsten MC; van Vugt-Lussenburg BM; Zeldenthuis T; de Vlieger JS; Commandeur JN; Vermeulen NP
    Chem Biol Interact; 2008 Jan; 171(1):96-107. PubMed ID: 17996858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Roles of key active-site residues in flavocytochrome P450 BM3.
    Noble MA; Miles CS; Chapman SK; Lysek DA; MacKay AC; Reid GA; Hanzlik RP; Munro AW
    Biochem J; 1999 Apr; 339 ( Pt 2)(Pt 2):371-9. PubMed ID: 10191269
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Filling a hole in cytochrome P450 BM3 improves substrate binding and catalytic efficiency.
    Huang WC; Westlake AC; Maréchal JD; Joyce MG; Moody PC; Roberts GC
    J Mol Biol; 2007 Oct; 373(3):633-51. PubMed ID: 17868686
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heterotropic and homotropic cooperativity by a drug-metabolising mutant of cytochrome P450 BM3.
    van Vugt-Lussenburg BM; Damsten MC; Maasdijk DM; Vermeulen NP; Commandeur JN
    Biochem Biophys Res Commun; 2006 Aug; 346(3):810-8. PubMed ID: 16777067
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phe120 contributes to the regiospecificity of cytochrome P450 2D6: mutation leads to the formation of a novel dextromethorphan metabolite.
    Flanagan JU; Maréchal JD; Ward R; Kemp CA; McLaughlin LA; Sutcliffe MJ; Roberts GC; Paine MJ; Wolf CR
    Biochem J; 2004 Jun; 380(Pt 2):353-60. PubMed ID: 14992686
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression, purification, and characterization of Bacillus subtilis cytochromes P450 CYP102A2 and CYP102A3: flavocytochrome homologues of P450 BM3 from Bacillus megaterium.
    Gustafsson MC; Roitel O; Marshall KR; Noble MA; Chapman SK; Pessegueiro A; Fulco AJ; Cheesman MR; von Wachenfeldt C; Munro AW
    Biochemistry; 2004 May; 43(18):5474-87. PubMed ID: 15122913
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The bacterial P450 BM3: a prototype for a biocatalyst with human P450 activities.
    Yun CH; Kim KH; Kim DH; Jung HC; Pan JG
    Trends Biotechnol; 2007 Jul; 25(7):289-98. PubMed ID: 17532492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A three-dimensional protein model for human cytochrome P450 2D6 based on the crystal structures of P450 101, P450 102, and P450 108.
    de Groot MJ; Vermeulen NP; Kramer JD; van Acker FA; Donné-Op den Kelder GM
    Chem Res Toxicol; 1996; 9(7):1079-91. PubMed ID: 8902262
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The dimeric form of flavocytochrome P450 BM3 is catalytically functional as a fatty acid hydroxylase.
    Neeli R; Girvan HM; Lawrence A; Warren MJ; Leys D; Scrutton NS; Munro AW
    FEBS Lett; 2005 Oct; 579(25):5582-8. PubMed ID: 16214136
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A model for human cytochrome P450 2D6 based on homology modeling and NMR studies of substrate binding.
    Modi S; Paine MJ; Sutcliffe MJ; Lian LY; Primrose WU; Wolf CR; Roberts GC
    Biochemistry; 1996 Apr; 35(14):4540-50. PubMed ID: 8605204
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protein engineering of the cytochrome P450 monooxygenase from Bacillus megaterium.
    Urlacher VB; Schmid RD
    Methods Enzymol; 2004; 388():208-24. PubMed ID: 15289074
    [No Abstract]   [Full Text] [Related]  

  • 17. A single mutation in cytochrome P450 BM3 changes substrate orientation in a catalytic intermediate and the regiospecificity of hydroxylation.
    Oliver CF; Modi S; Sutcliffe MJ; Primrose WU; Lian LY; Roberts GC
    Biochemistry; 1997 Feb; 36(7):1567-72. PubMed ID: 9048540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Binding of bufuralol, dextromethorphan, and 3,4-methylenedioxymethylamphetamine to wild-type and F120A mutant cytochrome P450 2D6 studied by resonance Raman spectroscopy.
    Bonifacio A; Keizers PH; Commandeur JN; Vermeulen NP; Robert B; Gooijer C; van der Zwan G
    Biochem Biophys Res Commun; 2006 May; 343(3):772-9. PubMed ID: 16563352
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Control of the stereo-selectivity of styrene epoxidation by cytochrome P450 BM3 using structure-based mutagenesis.
    Huang WC; Cullis PM; Raven EL; Roberts GC
    Metallomics; 2011 Apr; 3(4):410-6. PubMed ID: 21240430
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interactions of substrates at the surface of P450s can greatly enhance substrate potency.
    Hegde A; Haines DC; Bondlela M; Chen B; Schaffer N; Tomchick DR; Machius M; Nguyen H; Chowdhary PK; Stewart L; Lopez C; Peterson JA
    Biochemistry; 2007 Dec; 46(49):14010-7. PubMed ID: 18004886
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.